A detailed history of Caption Management, LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Caption Management, LLC holds 58,900 shares of BGNE stock, worth $11.4 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares
58,900
Holding current value
$11.4 Million
% of portfolio
0.23%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$125.51 - $229.3 $5.08 Million - $9.29 Million
40,500 Added 144.64%
68,500 $15.1 Million
Q3 2022

Nov 14, 2022

BUY
$131.8 - $202.24 $3.69 Million - $5.66 Million
28,000 New
28,000 $3.77 Million
Q1 2022

May 13, 2022

SELL
$146.52 - $269.56 $1.72 Million - $3.17 Million
-11,766 Reduced 61.28%
7,434 $1.4 Million
Q4 2021

Feb 11, 2022

BUY
$248.56 - $389.34 $4.77 Million - $7.48 Million
19,200 New
19,200 $5.2 Million

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $20B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.